D-threonine methyl ester hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: D-threonine methyl ester hydrochloride
• 英文别名: methyl (2R)-2-amino-3-hydroxybutanoate;hydrochloride
• 化学式: C₅H₁₁NO₃*ClH
• 分子量: 169.608
• InChiKey: OZSJLLVVZFTDEY-ZAQOELHGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.71
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  72.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  D-threonine methyl ester hydrochloride 、 N-Cyclohexyl-N-methyl-4-(3-formyl-4-nitrophenyl)-oxybutyramide 在 sodium acetate 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 (R)-2-{[1-{5-[3-(Cyclohexyl-methyl-carbamoyl)-propoxy]-2-nitro-phenyl}-meth-(E)-ylidene]-amino}-3-hydroxy-butyric acid methyl ester
  参考文献：
  名称：

  环状AMP磷酸二酯酶的抑制剂。2. N-环己基-N-甲基-4-[（1,2,3,5-四氢-2-氧代咪唑并[2,1-b]喹唑啉-7-基）-氧]丁酰胺（RS- 82856）。

  摘要：

  环状AMP磷酸二酯酶（PDE）抑制剂N-环己基-N-甲基-4-[（1,2,3,5-四氢-2-氧代咪唑并[2,1-b]喹唑啉-7-基的一系列类似物）氧基]丁酰胺（RS-82856，1）是通过侧链取代基，长度，位置，连接原子和母体杂环本身的系统变化而制备的。将该化合物评价为人血小板和大鼠或狗心脏组织中环状AMP磷酸二酯酶的抑制剂，以及作为ADP诱导的血小板聚集的抑制剂。类似物系列的结构活性相关性表明，对1,2,3,5-四氢咪唑并[2,1-b]喹唑啉-2-一杂环的取代基的空间体积以及侧链的位置和长度有明显的限制。作为环状AMP磷酸二酯酶（PDE）的抑制剂，随着亲脂性侧链的增加，效力逐渐增加。但是，在血小板凝集抑制研究中，活性达到1的最大值，而更多的亲脂性化合物的活性明显降低。杂环本身的主要变化（以异构体和其他羰基变化表示）也降低了活性。由一系列类似物1定义的分子特征与当前对环状AMP PDE的F

  DOI：

  10.1021/jm00385a012
• 作为产物：
  描述：

  D-threonine 在 盐酸 作用下， 以 甲醇 为溶剂， 生成 D-threonine methyl ester hydrochloride
  参考文献：
  名称：

  Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II

  摘要：

  一种化合物，是一种公式（I）的苯并[a]菲啉-11-甲酰胺衍生物，其中R1至R4中的每一个，它们相同或不同，被选择为氢、卤素、羟基、未取代或取代的C1-C6烷氧基、杂环氧基、未取代或取代的C1-C6烷基、硝基、氰基、叠氮基、酰肼基、CO2R10、CON(R12)2、OCON(R12)、SR10、SOR11、SO2(R11)、SO2N(R12)2、N(R12)2、NR10SO2R11、N(SO2R11)2NR10(CH2)nCN、NR10COR11、OCOR11或COR10；R5至R7中的每一个，它们相同或不同，被选择为氢、卤素、羟基、C1-C6烷氧基、C1-C6烷基、SR10和N(R12)2；Q是未取代或取代的C1-C6烷基，其被（i）未取代或取代的C1-C6烷基，（ii）羟基、前提是羟基不是在公式（I）中与Q相邻的任一N原子，（iii）CO2R10，或（iv）CON(R12)所取代；R1和R9，它们相同或不同，分别是氢或C1-C6烷基，或R8和R9连同它们连接到的氮原子形成饱和的5-或6-成员N-含杂环戊或六元环，可能包括一个额外的由O、N和S中选择的杂原子，或R8和R9中的一个是由O、N或S随机中断的烷基链，它连接到由Q表示的烷基链上的碳原子，以完成上述定义的饱和的5-或6-成员N-含杂环戊或六元环；或其药学上可接受的盐；但至少一个R1到R4不是氢。这些化合物是拓扑异构酶I和/或拓扑异构酶II的抑制剂，可用于治疗肿瘤，包括表达MDR的肿瘤。

  公开号：

  US20030139409A1

文献信息

• LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF
  申请人：YEDA RESEARCH AND DEVELOPMENT CO. LTD.

  公开号：US20160002269A1

  公开（公告）日：2016-01-07

  The present invention is directed to multinuclear lanthanides chiral clusters, based on phenyl-oxazoline-amide (POxA) ligands, and to methods of use thereof. The chiral clusters of this invention are highly fluorescent with high stability.

  本发明涉及基于苯基-噁唑啉酰胺（POxA）配体的多核镧系手性簇以及其使用方法。本发明的手性簇具有高荧光性能和高稳定性。
• [EN] NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE TRITERPÈNE EN TANT QU'INHIBITEURS DU VIH
  申请人：HETERO LABS LTD

  公开号：WO2020165741A1

  公开（公告）日：2020-08-20

  The present invention relates to novel triterpene derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and ring are as defined herein. The invention also relates to novel triterpene derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

  本发明涉及公式（I）的新型三萜衍生物；及其药学上可接受的盐，其中R1、R2、R3、R4和环如本文所定义。该发明还涉及新型三萜衍生物、相关化合物和药物组合物，用于治疗病毒性疾病，特别是HIV介导的疾病。
• .beta.-thiopropionyl-aminoacid derivatives and their use as
  申请人：SmithKline Beecham p.l.c.

  公开号：US06048852A1

  公开（公告）日：2000-04-11

  A method of treatment of bacterial infections in humans or animals which comprises administering, in combination with a .beta.-lactam antibiotic, a therapeutically effective amount of an amino acid derivative of Formula (I) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, ##STR1## wherein: R is hydrogen, a salt forming cation or an in vivo hydrolysable ester-forming group; R.sub.1 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms or by a mercapto, (C.sub.1-6)alkoxy, hydroxy, amino, nitro, carboxy, (C.sub.1-6)alkylcarbonyloxy, (C.sub.1-6)alkoxycarbonyl, formyl or (C.sub.1-6)alkylcarbonyl group, (C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl(C.sub.1-6)alkyl, heterocyclyl or heterocyclyl(C.sub.1-6)alkyl; R.sub.2 is hydrogen, (C.sub.1-6)alkyl or aryl(C.sub.1-6)alkyl; R.sub.3 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms, (C.sub.3-7)cycloalkyl, fused aryl(C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n, heterocyclyl or heterocyclyl-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n, where m is 0 to 3, n is 1 to 3, each R.sub.10 and R.sub.11 is independently hydrogen or (C.sub.1-4)alkyl and X is O, S(O).sub.x where x is 0-2, or a bond; R.sub.4 is hydrogen, or an in vivo hydrolysable acyl group; and R.sub.5 and R.sub.6 are independently hydrogen and (C.sub.1-6)alkyl or together represent (CH.sub.2).sub.p where p is 2 to 5. Some compounds are claimed per se.

  一种治疗人类或动物细菌感染的方法，包括与β-内酰胺类抗生素联合给药，给予公式(I)的氨基酸衍生物的治疗有效量或其药用可接受的盐、溶剂化合物或体内可水解酯的治疗有效量，其中：R为氢、形成盐的阳离子或体内可水解酯形成基团；R.sub.1为氢、(C.sub.1-6)烷基，可选地被高达三个卤素原子或巯基、(C.sub.1-6)烷氧基、羟基、氨基、硝基、羧基、(C.sub.1-6)烷基羰氧基、(C.sub.1-6)烷氧羰基、甲酰基或(C.sub.1-6)烷基羰基取代，(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基(C.sub.1-6)烷基，杂环烷基或杂环烷基(C.sub.1-6)烷基；R.sub.2为氢，(C.sub.1-6)烷基或芳基(C.sub.1-6)烷基；R.sub.3为氢，(C.sub.1-6)烷基，可选地被高达三个卤素原子取代，(C.sub.3-7)环烷基，融合的芳基(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，杂环烷基或杂环烷基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，其中m为0至3，n为1至3，每个R.sub.10和R.sub.11独立地为氢或(C.sub.1-4)烷基，X为O，S(O).sub.x，其中x为0-2，或键；R.sub.4为氢，或体内可水解的酰基；R.sub.5和R.sub.6独立地为氢和(C.sub.1-6)烷基，或一起代表(CH.sub.2).sub.p，其中p为2至5。一些化合物本身被要求。
• [EN] 1-[(INDOL-3-YL)CARBONYL] PIPERAZINE DERIVATIVES<br/>[FR] DERIVES DE 1-[(INDOL-3-YL)CARBONYL] PIPERAZINE
  申请人：AKZO NOBEL NV

  公开号：WO2004000832A1

  公开（公告）日：2003-12-31

  The present invention relates to 1-[(indol-3-yl)carbonyl]piperazine derivative according to the general formula (I), wherein R represents 1-4 substituents independently selected from H, (C1-4)alkyl (optionally substituted with halogen), (C 1-4)alkyloxy (optionally substituted with halogen), halogen, OH, NH2, CN and NO2; R1 is (C5-8)cycloalkyl or (C5-8)cycloalkenyl; R2 is H, methyl or ethyl; R3, R3', R4' R4', R5, R5' and R6' are independently hydrogen or (C1-4)alkyl, optionally substituted with (C1-4)alkyloxy, halogen or OH; R6 is hydrogen or (C1-4)alkyl, optionally substituted with (C1-4)alkyloxy, halogen or OH; or R6 forms together with R7 a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S; R7 forms together with R6 a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S; or R7 is H, (C1-4)alkyl or (C3-5)cycloalkyl, the alkyl groups being optionally substituted with OH, halogen or (C1-4)alkyloxy; or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said 1-[(indol-3-yl)carbonyl]piperazine derivatives, and to the use of these derivatives in the treatment of pain, such as peri-operative pain, chronic pain neuropathic pain, cancer pain, and pain and spasticity associated with multiple sclerosis.

  本发明涉及根据通式（I）的1-[(indol-3-yl)carbonyl]哌嗪衍生物，其中R代表独立选择的1-4个取代基，包括H，（C1-4）烷基（可选择用卤素取代），（C1-4）烷氧基（可选择用卤素取代），卤素，羟基，氨基，氰基和硝基；R1为（C5-8）环烷基或（C5-8）环烯基；R2为H，甲基或乙基；R3，R3'，R4'，R4'，R5，R5'和R6'独立地为氢或（C1-4）烷基，可选择用（C1-4）烷氧基，卤素或羟基取代；R6为氢或（C1-4）烷基，可选择用（C1-4）烷氧基，卤素或羟基取代；或R6与R7一起形成一个含有O和S等进一步杂原子的4-7元饱和杂环；R7与R6一起形成一个含有O和S等进一步杂原子的4-7元饱和杂环；或R7为H，（C1-4）烷基或（C3-5）环烷基，烷基基团可选择用羟基，卤素或（C1-4）烷氧基取代；或其药学上可接受的盐。该发明还涉及包含所述1-[(indol-3-yl)carbonyl]哌嗪衍生物的药物组合物，并且涉及在治疗疼痛方面使用这些衍生物，如围手术疼痛，慢性疼痛，神经病性疼痛，癌症疼痛以及与多发性硬化症相关的疼痛和痉挛。
• [EN] BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II<br/>[FR] DERIVES DE BENZO[A]PHENAZINE-11-CARBOXAMIDE ET LEUR UTILISATION COMME INHIBITEURS COMMUNS DE LA TOPOMERASE I ET II
  申请人：XENOVA LTD

  公开号：WO2001046157A1

  公开（公告）日：2001-06-28

  A compound which is a benzo[a]phenazine-11-carboxamide derivative of formula (I) wherein each of R1 to R4, which are the same or different, is selected from hydrogen, halogen, hydroxyl, C¿1?-C6 alkoxy which is unsubstituted or substituted, heteroaryloxy, C1-C6 alkyl which is unsubstituted or substituted, nitro, cyano, azido, amidoxime, CO2R?10, CON(R12)¿2, OCON(R?12), SR10, SOR11, SO¿2(R11), SO2N(R12)2, N(R12)2, NR10SO2R11, N(SO¿2R?11)2NR10(CH2)nCN, NR?10COR11, OCOR11 or COR10¿; each of R5 to R7, which are the same or different, is selected from hydrogen, halogen, hydroxy, C¿1?-C6 alkoxy, C1-C6 alkyl, SR?10¿ and N(R12)2; Q is C1-C6 alkylene which is unsubstituted or substituted by (i) C1-C6 alkyl which is unsubstituted or substituted, (ii) hydroxy, provided that the hydroxy group is not α to either of the N atoms adjacent to Q in formula (I), (iii) CO2R10, or (iv) CON(R?12); R8 and R9¿, which are the same or different, are each hydrogen or C¿1?-C6 alkyl, or R?8 and R9¿ together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered N-containing heterocyclic ring which may include one additional heteroatom selected from O, N and S, or one of R?8 and R9¿ is an alkylene chain optionally interrupted by O, N or S, which is attached to a carbon atom on the alkylene chain represented by Q to complete a saturated 5- or 6-membered N-containing heterocyclic ring as defined above; or a pharmaceutically acceptable salt thereof; with the proviso that at least one R1 to R4 is other than hydrogen. These compounds are inhibitors of topoisomerase I and/or topoisomerase II and can be used to treat tumours, including tumours which express MDR.

  化合物是公式（I）的苯并[a]菲噻唑-11-羧酰胺衍生物，其中R1至R4中的每一个，相同或不同，从氢，卤素，羟基，未取代或取代的C1-C6烷氧基，杂环氧基，未取代或取代的C1-C6烷基，硝基，氰基，偶氮基，酰肟基，CO2R10，CON（R12）2，OCON（R12），SR10，SOR11，SO2（R11），SO2N（R12）2，N（R12）2，NR10SO2R11，N（SO2R11）2NR10（CH2）nCN，NR10COR11，OCOR11或COR10中选择；R5至R7中的每一个，相同或不同，从氢，卤素，羟基，C1-C6烷氧基，C1-C6烷基，SR10和N（R12）2中选择；Q是未取代或取代的C1-C6烷基，由（i）未取代或取代的C1-C6烷基，（ii）羟基，前提是羟基不是在公式（I）中与Q相邻的任何一个氮原子的α位上，（iii）CO2R10或（iv）CON（R12）取代的；R8和R9'，相同或不同，均为氢或C1-C6烷基，或R8和R9'与它们连接的氮原子共同形成饱和的5-或6-成员N-含杂环，该杂环可以包括从O，N和S中选择的一个额外的杂原子，或R8和R9'中的一个是由O，N或S间断的烷基链，该烷基链连接到由Q表示的烷基链上的碳原子以形成上述定义的饱和的5-或6-成员N-含杂环；或其药学上可接受的盐；但至少有一个R1至R4不是氢。这些化合物是拓扑异构酶I和/或拓扑异构酶II的抑制剂，可用于治疗肿瘤，包括表达MDR的肿瘤。